TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer

References

• Ahmed N, Stenvers KL. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol. 2013;3:256.
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–16. doi:10.3322/caac.21387.
   PubMed Web of Science ®Google Scholar
• James FR, Jiminez-Linan M, Alsop J, Mack M, Song H, Brenton JD, Pharoah PDP, Ali HR. Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer. BMC Cancer. 2017;17(1):657. doi:10.1186/s12885-017-3585-x.
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–213. doi:10.1056/NEJMoa020177.
   PubMed Web of Science ®Google Scholar
• Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2012;124(2):192–198. doi:10.1016/j.ygyno.2011.09.039.
   PubMed Web of Science ®Google Scholar
• Webb JR, Milne K, Watson P, deLeeuw RJ, Nelson BH. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res. 2014;20(2):434–444. doi:10.1158/1078-0432.CCR-13-1877.
   PubMed Web of Science ®Google Scholar
• Geller MA, Knorr DA, Hermanson DA, Pribyl L, Bendzick L, Mccullar V, Miller JS, Kaufman DS. Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model. Cytotherapy. 2013;15(10):1297–1306. doi:10.1016/j.jcyt.2013.05.022.
   PubMed Web of Science ®Google Scholar
• Felices M, Chu S, Kodal B, Bendzick L, Ryan C, Lenvik AJ, Boylan KLM, Wong HC, Skubitz APN, Miller JS, et al. IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer. Gynecol Oncol. 2017;145(3):453–461. doi:10.1016/j.ygyno.2017.02.028.
   PubMed Web of Science ®Google Scholar
• Carlsten M, Björkström NK, Norell H, Bryceson Y, van Hall T, Baumann BC, Hanson M, Schedvins K, Kiessling R, Ljunggren H-G, et al. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 2007;67(3):1317–1325. doi:10.1158/0008-5472.CAN-06-2264.
   PubMed Web of Science ®Google Scholar
• Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, Dusenbery K, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13(1):98–107.
   PubMed Web of Science ®Google Scholar
• Yang Y, Lim O, Kim TM, Ahn Y-O, Choi H, Chung H, Min B, Her JH, Cho SY, Keam B, et al. Phase I study of random healthy donor-derived allogeneic natural killer cell therapy in patients with malignant lymphoma or advanced solid tumors. Cancer Immunol Res. 2016;4(3):215–224. doi:10.1158/2326-6066.CIR-15-0118.
   PubMed Web of Science ®Google Scholar
• Hoogstad-van Evert J, Bekkers R, Ottevanger N, Schaap N, Hobo W, Jansen JH, Massuger L, Dolstra H. Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study). Medicine (Baltimore). 2019;98(5):e14290. doi:10.1097/MD.0000000000014290.
   PubMed Web of Science ®Google Scholar
• Yigit R, Massuger LFAG, Figdor CG, Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol. 2010;117(2):366–372. doi:10.1016/j.ygyno.2010.01.019.
   PubMed Web of Science ®Google Scholar
• Yigit R, Figdor CG, Zusterzeel PLM, Pots JM, Torensma R, Massuger LFAG. Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer. Eur J Cancer. 2011;47(12):1883–1889. doi:10.1016/j.ejca.2011.03.026.
   PubMed Web of Science ®Google Scholar
• Rodriguez GM, Galpin K, McCloskey C, Vanderhyden B. The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy. Cancers (Basel). 2018;10(8):242. doi:10.3390/cancers10080242.
   PubMed Web of Science ®Google Scholar
• Giuntoli RL 2nd, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, Oelke M. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res. 2009;29(8):2875–2884.
   PubMed Web of Science ®Google Scholar
• Fogel LA, Yokoyama WM, French AR. Natural killer cells in human autoimmune disorders. Arthritis Res Ther. 2013;15(4):216. doi:10.1186/ar4232.
   PubMed Web of Science ®Google Scholar
• Mandal A, Viswanathan C. Natural killer cells: in health and disease. Hematol Oncol Stem Cell Ther. 2015;8(2):47–55. doi:10.1016/j.hemonc.2014.11.006.
   PubMedGoogle Scholar
• Baci D, Bosi A, Gallazzi M, Rizzi M, Noonan DM, Poggi A, Bruno A, Mortara L. The ovarian cancer tumor immune microenvironment (TIME) as target for therapy: a focus on innate immunity cells as therapeutic effectors. Int J Mol Sci. 2020;21(9):3125. doi:10.3390/ijms21093125.
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Kim N, Kim HS. Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy. Exp Mol Med. 2017;49(3):e311. doi:10.1038/emm.2017.42.
   PubMed Web of Science ®Google Scholar
• Sakisaka T, Takai Y. Biology and pathology of nectins and nectin-like molecules. Curr Opin Cell Biol. 2004;16(5):513–521. doi:10.1016/j.ceb.2004.07.007.
   PubMed Web of Science ®Google Scholar
• Fuchs A, Colonna M. The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance. Semin Cancer Biol. 2006;16(5):359–366. doi:10.1016/j.semcancer.2006.07.002.
   PubMed Web of Science ®Google Scholar
• Cerboni C, Fionda C, Soriani A, Zingoni A, Doria M, Cippitelli M, Santoni A.. The DNA damage response: a common pathway in the regulation of NKG2D and DNAM-1 ligand expression in normal, infected, and cancer cells. Front Immunol. 2013;4:508.
   Web of Science ®Google Scholar
• Smazynski J, Hamilton PT, Thornton S, Milne K, Wouters MCA, Webb JR, Nelson BH. The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers. Gynecol Oncol. 2020;158(1):167–177. doi:10.1016/j.ygyno.2020.04.689.
   PubMed Web of Science ®Google Scholar
• Martinet L, Smyth MJ. Balancing natural killer cell activation through paired receptors. Nat Rev Immunol. 2015;15(4):243. doi:10.1038/nri3799.
   PubMed Web of Science ®Google Scholar
• Deuss FA, Gully BS, Rossjohn J, Berry R. Recognition of nectin-2 by the natural killer cell receptor T cell immunoglobulin and ITIM domain (TIGIT). J Biol Chem. 2017;292(27):11413–11422. doi:10.1074/jbc.M117.786483.
   PubMed Web of Science ®Google Scholar
• Wang H, Qi J, Zhang S, Li Y, Tan S, Gao GF. Binding mode of the side-by-side two-IgV molecule CD226/DNAM-1 to its ligand CD155/Necl-5. Proc Natl Acad Sci U S A. 2019;116(3):988–996. doi:10.1073/pnas.1815716116.
   PubMed Web of Science ®Google Scholar
• Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T, Kitamura T, Nicholl J, Sutherland GR, Lanier LL, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity. 1996;4(6):573–581. doi:10.1016/S1074-7613(00)70060-4.
   PubMed Web of Science ®Google Scholar
• Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, Levine Z, Beiman M, Dassa L, Achdout H, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A. 2009;106(42):17858–17863.
   PubMed Web of Science ®Google Scholar
• Liu S, Zhang H, Li M, Hu D, Li C, Ge B, Jin B, Fan Z. Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ. 2013;20(3):456–464. doi:10.1038/cdd.2012.141.
   PubMed Web of Science ®Google Scholar
• Sanchez-Correa B, Valhondo I, Hassouneh F, Lopez-Sejas N, Pera A, Bergua JM, Arcos MJ, Bañas H, Casas-Avilés I, Durán E, et al. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: novel immune checkpoints for natural killer cell-based cancer immunotherapy. Cancers (Basel). 2019;11(6):877. doi:10.3390/cancers11060877.
   PubMed Web of Science ®Google Scholar
• Sanchez-Correa B, Gayoso I, Bergua JM, Casado JG, Morgado S, Solana R, Tarazona R. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunol Cell Biol. 2012;90(1):109–115. doi:10.1038/icb.2011.15.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wu N, Lu Y, Davidson D, Colonna M, Veillette A. DNAM-1 controls NK cell activation via an ITT-like motif. J Exp Med. 2015;212(12):2165–2182. doi:10.1084/jem.20150792.
   PubMed Web of Science ®Google Scholar
• Carlsten M, Norell H, Bryceson YT, Poschke I, Schedvins K, Ljunggren HG, Kiessling R, Malmberg KJ, et al. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol. 2009;183(8):4921–4930. doi:10.4049/jimmunol.0901226.
   PubMed Web of Science ®Google Scholar
• Hoogstad-van Evert JS, Maas RJ, Van Der Meer J, Cany J, Van Der Steen S, Jansen JH, Miller JS, Bekkers R, Hobo W, Massuger L, Dolstra H, et al. Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients. Oncotarget. 2018;9(78):34810–34820. doi:10.18632/oncotarget.26199.
   PubMedGoogle Scholar
• Hattori N, Kawaguchi Y, Sasaki Y, Shimada S, Murai S, Abe M, Baba Y, Watanuki M, Fujiwara S, Arai N, et al. Monitoring TIGIT/DNAM-1 and PVR/PVRL2 immune checkpoint expression levels in allogeneic stem cell transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant. 2019;25(5):861–867. doi:10.1016/j.bbmt.2019.01.013.
   PubMed Web of Science ®Google Scholar
• Sarhan D, Cichocki F, Zhang B, Yingst A, Spellman SR, Colley S, Verneris MR, Blazar BR, Miller JS, et al. Adaptive NK cells with low TIGIT expression are inherently resistant to myeloid-derived suppressor cells. Cancer Res. 2016;76(19):5696–5706. doi:10.1158/0008-5472.CAN-16-0839.
   PubMed Web of Science ®Google Scholar
• Wang F, Hou H, Wu S, Tang Q, Liu W, Huang M, Yin B, Huang J, Mao L, Lu Y, Sun Z, et al. TIGIT expression levels on human NK cells correlate with functional heterogeneity among healthy individuals. Eur J Immunol. 2015;45(10):2886–2897. doi:10.1002/eji.201545480.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, Wang Z, Wu Q, Peng H, Wei H, Sun R, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19(7):723–732. doi:10.1038/s41590-018-0132-0.
   PubMed Web of Science ®Google Scholar
• Xu F, Sunderland A, Zhou Y, Schulick RD, Edil BH, Zhu Y. Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions. Cancer Immunol Immunother. 2017;66(10):1367–1375. doi:10.1007/s00262-017-2031-x.
   PubMed Web of Science ®Google Scholar
• Giannattasio A, Weil S, Kloess S, Ansari N, Stelzer EHK, Cerwenka A, Steinle A, Koehl U, Koch J. Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids. BMC Cancer. 2015;15(1):351. doi:10.1186/s12885-015-1321-y.
   PubMed Web of Science ®Google Scholar
• Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA. Spheroid-based drug screen: considerations and practical approach. Nat Protoc. 2009;4(3):309–324. doi:10.1038/nprot.2008.226.
   PubMed Web of Science ®Google Scholar
• Kiessling R, Klein E, Wigzell H. “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol. 1975;5(2):112–117. doi:10.1002/eji.1830050208.
   PubMed Web of Science ®Google Scholar
• Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer. 1975;16(2):216–229. doi:10.1002/ijc.2910160204.
   PubMed Web of Science ®Google Scholar
• Lugthart G, van Ostaijen-ten Dam MM, van Tol MJD, Lankester AC, Schilham MW. CD56(dim)CD16⁻ NK cell phenotype can be induced by cryopreservation. Blood. 2015;125(11):1842–1843. doi:10.1182/blood-2014-11-610311.
   PubMed Web of Science ®Google Scholar
• Xu Y, Sun J, Sheard MA, Tran HC, Wan Z, Liu WY, Asgharzadeh S, Sposto R, Wu HW, Seeger RC, et al. Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1. Cancer Immunol Immunother. 2013;62(10):1637–1648. doi:10.1007/s00262-013-1466-y.
   PubMed Web of Science ®Google Scholar
• Allan DS, Rybalov B, Awong G, Zúñiga-Pflücker JC, Kopcow HD, Carlyle JR, Strominger JL. TGF-β affects development and differentiation of human natural killer cell subsets. Eur J Immunol. 2010;40(8):2289–2295. doi:10.1002/eji.200939910.
   PubMed Web of Science ®Google Scholar
• Tran HC, Wan Z, Sheard MA, Sun J, Jackson JR, Malvar J, Xu Y, Wang L, Sposto R, Kim ES, et al. TGFβR1 blockade with galunisertib (LY2157299) enhances anti-neuroblastoma activity of the anti-GD2 antibody dinutuximab (ch14.18) with natural killer cells. Clin Cancer Res. 2017;23(3):804–813. doi:10.1158/1078-0432.CCR-16-1743.
   PubMed Web of Science ®Google Scholar
• Wilson EB, El-Jawhari JJ, Neilson AL, Hall GD, Melcher AA, Meade JL, Cook GP. Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLoS One. 2011;6(9):e22842. doi:10.1371/journal.pone.0022842.
   PubMed Web of Science ®Google Scholar
• Sun H, Huang Q, Huang M, Wen H, Lin R, Zheng M, Qu K, Li K, Wei H, Xiao W, et al. Human CD96 correlates to natural killer cell exhaustion and predicts the prognosis of human hepatocellular carcinoma. Hepatology. 2019;70(1):168–183. doi:10.1002/hep.30347.
   PubMed Web of Science ®Google Scholar
• Vujanovic L, Chuckran C, Lin Y, Ding F, Sander CA, Santos PM, Lohr J, Mashadi-Hossein A, Warren S, White A, et al. CD56(dim) CD16(-) natural killer cell profiling in melanoma patients receiving a cancer vaccine and interferon-alpha. Front Immunol. 2019;10:14. doi:10.3389/fimmu.2019.00014.
   PubMed Web of Science ®Google Scholar
• Romee R, Foley B, Lenvik T, Wang Y, Zhang B, Ankario D, Luo X, Cooley S, Verneris M, Walcheck B, Miller J, et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood. 2013;121(18):3599–3608. doi:10.1182/blood-2012-04-425397.
   PubMed Web of Science ®Google Scholar
• Grzywacz B, Kataria N, Verneris MR. CD56dimCD16+ NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. Leukemia. 2007;21(2):356–359. doi:10.1038/sj.leu.2404499.
   PubMed Web of Science ®Google Scholar
• Szczepanski MJ, Szajnik M, Welsh A, Foon KA, Whiteside TL, Boyiadzis M. Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors. Cancer Immunol Immunother. 2010;59(1):73–79. doi:10.1007/s00262-009-0724-5.
   PubMed Web of Science ®Google Scholar
• de Rham C, Ferrari-Lacraz S, Jendly S, Schneiter G, Dayer J-M, Villard J. The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors. Arthritis Res Ther. 2007;9(6):R125. doi:10.1186/ar2336.
   PubMed Web of Science ®Google Scholar